+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Gene Therapy Market by Therapy, Indication, End-Use - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010618
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer Gene Therapy Market grew from USD 2.20 billion in 2023 to USD 2.75 billion in 2024. It is expected to continue growing at a CAGR of 20.22%, reaching USD 7.99 billion by 2030.

Cancer gene therapy involves the modification of a patient's genetic material to treat or prevent cancer. It is a promising field, aiming to correct or replace defective genes, enhance the patient's immune response, or deliver genes that kill cancer cells directly. The necessity for cancer gene therapy arises from the limitations of traditional cancer treatments and the increasing global cancer incidence. Its applications span across a variety of gene delivery methods, such as viral vectors, plasmid DNA, and RNA therapies, targeting a range of cancer types, which include lung, blood, breast, and prostate cancers. End-use sectors include healthcare facilities, research institutes, and biotech companies.

The market is influenced by key growth factors like rising R&D investments, technological advances in gene editing tools like CRISPR/Cas9, and a growing acceptance of personalized medicine. Emerging opportunities lie in expanding therapeutic areas, development of non-viral delivery systems, and increasing collaboration between public and private sectors. However, challenges such as high treatment costs, regulatory hurdles, ethical concerns, and potential side effects hinder market expansion. Stringent regulatory requirements and limited patient population in clinical trials also add complexity to market growth.

For innovation, the development of safer, more efficient gene delivery systems and the exploration of combinatorial approaches using gene therapy with other treatments - such as immunotherapy - could be beneficial. Additionally, investment in AI and machine learning to predict therapy responses and optimize treatment protocols offers considerable potential. The market is dynamic, characterized by rapid technological advancements and increasing strategic partnerships. Continued investment in research and addressing ethical and safety concerns will play crucial roles in enhancing treatment efficacy and expanding market reach. Companies should focus on regulatory compliance and forming collaborations to overcome entry barriers and leverage upcoming opportunities effectively.

Understanding Market Dynamics in the Cancer Gene Therapy Market

The Cancer Gene Therapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Need for treatment options to tackle the growing prevalence of cancers
    • Increasing R&D activities to stimulate cancer research
    • Government support for the development of cancer treatment methods and gene therapy
  • Market Restraints
    • Risk of adverse immune reaction and recall of products
  • Market Opportunities
    • Expansion of gene therapy cancer centers worldwide
    • Utilization of AI and ML to accelerate cell and gene therapies
  • Market Challenges
    • Regulatory considerations concerning the safety of gene therapy

Exploring Porter’s Five Forces for the Cancer Gene Therapy Market

Porter’s Five Forces framework further strengthens the insights of the Cancer Gene Therapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cancer Gene Therapy Market

External macro-environmental factors deeply influence the performance of the Cancer Gene Therapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cancer Gene Therapy Market

The Cancer Gene Therapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cancer Gene Therapy Market

The Cancer Gene Therapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cancer Gene Therapy Market

The Cancer Gene Therapy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Achieve Life Sciences, Inc., Adaptimmune Therapeutics PLC, Alaunos Therapeutics Inc., Amgen, Inc., Bayer AG, Biogen Inc., Bluebird Bio Inc., Bristol-Myers Squibb Company, Candel Therapeutics, Elevate Bio Inc., Genelux Corporation, Gilead Sciences, Inc., GlaxoSmithKline Inc., ImmunityBio, Inc., Merck KGaA, Precigen, Inc., Sarepta Therapeutics, Inc., Shanghai Sunway Biotech Co., Ltd., and Sibiono GeneTech Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Therapy
    • Gene Induced Immunotherapy
    • Gene Transfer
    • Oncolytic Virotherapy
  • Indication
    • Breast Cancer
    • Liver Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
  • End-Use
    • Biopharmaceutical Companies
    • Diagnostic Centers
    • Oncology Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Need for treatment options to tackle the growing prevalence of cancers
5.1.1.2. Increasing R&D activities to stimulate cancer research
5.1.1.3. Government support for the development of cancer treatment methods and gene therapy
5.1.2. Restraints
5.1.2.1. Risk of adverse immune reaction and recall of products
5.1.3. Opportunities
5.1.3.1. Expansion of gene therapy cancer centers worldwide
5.1.3.2. Utilization of AI and ML to accelerate cell and gene therapies
5.1.4. Challenges
5.1.4.1. Regulatory considerations concerning the safety of gene therapy
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cancer Gene Therapy Market, by Therapy
6.1. Introduction
6.2. Gene Induced Immunotherapy
6.3. Gene Transfer
6.4. Oncolytic Virotherapy
7. Cancer Gene Therapy Market, by Indication
7.1. Introduction
7.2. Breast Cancer
7.3. Liver Cancer
7.4. Lung Cancer
7.5. Ovarian Cancer
7.6. Pancreatic Cancer
7.7. Prostate Cancer
8. Cancer Gene Therapy Market, by End-Use
8.1. Introduction
8.2. Biopharmaceutical Companies
8.3. Diagnostic Centers
8.4. Oncology Research Institutes
9. Americas Cancer Gene Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Gene Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Gene Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CANCER GENE THERAPY MARKET RESEARCH PROCESS
FIGURE 2. CANCER GENE THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CANCER GENE THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CANCER GENE THERAPY MARKET DYNAMICS
TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE INDUCED IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE TRANSFER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 32. CANADA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 33. CANADA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. CANADA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 36. MEXICO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. MEXICO CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 49. CHINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 50. CHINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. CHINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 52. INDIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 53. INDIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. INDIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 58. JAPAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 59. JAPAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. JAPAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 76. THAILAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 77. THAILAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. THAILAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. DENMARK CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 87. DENMARK CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. DENMARK CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 89. EGYPT CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 90. EGYPT CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. EGYPT CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 92. FINLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 93. FINLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. FINLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 96. FRANCE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. FRANCE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 99. GERMANY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. GERMANY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 104. ITALY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 105. ITALY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. ITALY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 113. NORWAY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 114. NORWAY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. NORWAY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 116. POLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 117. POLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. POLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 119. QATAR CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 120. QATAR CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. QATAR CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 131. SPAIN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 132. SPAIN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. SPAIN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 140. TURKEY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 141. TURKEY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. TURKEY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 149. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 150. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cancer Gene Therapy market, which are profiled in this report, include:
  • Abeona Therapeutics Inc.
  • Achieve Life Sciences, Inc.
  • Adaptimmune Therapeutics PLC
  • Alaunos Therapeutics Inc.
  • Amgen, Inc.
  • Bayer AG
  • Biogen Inc.
  • Bluebird Bio Inc.
  • Bristol-Myers Squibb Company
  • Candel Therapeutics
  • Elevate Bio Inc.
  • Genelux Corporation
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Inc.
  • ImmunityBio, Inc.
  • Merck KGaA
  • Precigen, Inc.
  • Sarepta Therapeutics, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.

Methodology

Loading
LOADING...